OBJECTIVE: The purpose of our study was to determine the efficacy of using the Choyke questionnaire to stratify the potential risk for nephrogenic systemic fibrosis (NSF) before a gadolinium-enhanced MRI examination and to compare the economic impact of such an approach with universal blood sampling before gadolinium-enhanced MRI. MATERIALS AND METHODS: We retrospectively reviewed the records of 1,086 consecutive outpatients referred for gadolinium-enhanced MRI. For inclusion, patients were required to have an estimated glomerular filtration rate (eGFR) result within 30 days before gadolinium-enhanced MRI and a completed Choyke questionnaire, first when the order was placed and again at the point of service. Questionnaire results were dichotomized into "No" (all no responses in both questionnaires) or "Yes" (one or more yes responses in either questionnaire) response groups for comparison with the corresponding eGFR. An economic impact assessment for using the questionnaire to identify "at risk" patients was performed using a decision-analytic model. RESULTS: Entry criteria were met in 665 of 1,086 (61.2%) patients. Zero patients in the No (n = 287) and seven in the Yes (1.9%) group (n = 378) had an eGFR of less than 30 mL/min/1.73 m(2). Using the 100% sensitivity achieved in identifying higher risk patients (seven patients; 95% CI, 59-100%), the questionnaire could save $4.52 per patient. At the lower boundary of the 95% CI for sensitivity, the savings incurred would come at the expense of administering gadolinium to 0.4% of patients with an eGFR less than 30 mL/min/1.73 m(2). CONCLUSION: The Choyke questionnaire effectively stratifies patients for NSF risk before gadolinium-enhanced MRI, offering potential cost savings and streamlined care.
OBJECTIVE: The purpose of our study was to determine the efficacy of using the Choyke questionnaire to stratify the potential risk for nephrogenic systemic fibrosis (NSF) before a gadolinium-enhanced MRI examination and to compare the economic impact of such an approach with universal blood sampling before gadolinium-enhanced MRI. MATERIALS AND METHODS: We retrospectively reviewed the records of 1,086 consecutive outpatients referred for gadolinium-enhanced MRI. For inclusion, patients were required to have an estimated glomerular filtration rate (eGFR) result within 30 days before gadolinium-enhanced MRI and a completed Choyke questionnaire, first when the order was placed and again at the point of service. Questionnaire results were dichotomized into "No" (all no responses in both questionnaires) or "Yes" (one or more yes responses in either questionnaire) response groups for comparison with the corresponding eGFR. An economic impact assessment for using the questionnaire to identify "at risk" patients was performed using a decision-analytic model. RESULTS: Entry criteria were met in 665 of 1,086 (61.2%) patients. Zero patients in the No (n = 287) and seven in the Yes (1.9%) group (n = 378) had an eGFR of less than 30 mL/min/1.73 m(2). Using the 100% sensitivity achieved in identifying higher risk patients (seven patients; 95% CI, 59-100%), the questionnaire could save $4.52 per patient. At the lower boundary of the 95% CI for sensitivity, the savings incurred would come at the expense of administering gadolinium to 0.4% of patients with an eGFR less than 30 mL/min/1.73 m(2). CONCLUSION: The Choyke questionnaire effectively stratifies patients for NSF risk before gadolinium-enhanced MRI, offering potential cost savings and streamlined care.
Authors: Peter Marckmann; Lone Skov; Kristian Rossen; Anders Dupont; Mette Brimnes Damholt; James Goya Heaf; Henrik S Thomsen Journal: J Am Soc Nephrol Date: 2006-08-02 Impact factor: 10.121
Authors: Andrew S Levey; Josef Coresh; Ethan Balk; Annamaria T Kausz; Adeera Levin; Michael W Steffes; Ronald J Hogg; Ronald D Perrone; Joseph Lau; Garabed Eknoyan Journal: Ann Intern Med Date: 2003-07-15 Impact factor: 25.391
Authors: Mellena D Bridges; Brandon S St Amant; Rebecca B McNeil; Joseph G Cernigliaro; Jamie P Dwyer; Peter M Fitzpatrick Journal: AJR Am J Roentgenol Date: 2009-06 Impact factor: 3.959
Authors: Krishna Juluru; Jens Vogel-Claussen; Katarzyna J Macura; Ihab R Kamel; Alexander Steever; David A Bluemke Journal: Radiographics Date: 2008-11-19 Impact factor: 5.333
Authors: Luis M De León-Rodríguez; André F Martins; Marco C Pinho; Neil M Rofsky; A Dean Sherry Journal: J Magn Reson Imaging Date: 2015-05-14 Impact factor: 4.813
Authors: Henrik S Thomsen; Sameh K Morcos; Torsten Almén; Marie-France Bellin; Michele Bertolotto; Georg Bongartz; Olivier Clement; Peter Leander; Gertraud Heinz-Peer; Peter Reimer; Fulvio Stacul; Aart van der Molen; Judith A W Webb Journal: Eur Radiol Date: 2012-08-04 Impact factor: 5.315
Authors: David E Gerber; William C Putnam; Farjana J Fattah; Kemp H Kernstine; Rolf A Brekken; Ivan Pedrosa; Rachael Skelton; Jessica M Saltarski; Robert E Lenkinski; Richard D Leff; Chul Ahn; Chyndhri Padmanabhan; Vaidehi Chembukar; Sahba Kasiri; Raja Reddy Kallem; Indhumathy Subramaniyan; Qing Yuan; Quyen N Do; Yin Xi; Scott I Reznik; Lorraine Pelosof; Brandon Faubert; Ralph J DeBerardinis; James Kim Journal: Clin Cancer Res Date: 2020-08-26 Impact factor: 12.531
Authors: Nicola Schieda; Jason I Blaichman; Andreu F Costa; Rafael Glikstein; Casey Hurrell; Matthew James; Pejman Jabehdar Maralani; Wael Shabana; An Tang; Anne Tsampalieros; Christian B van der Pol; Swapnil Hiremath Journal: Can J Kidney Health Dis Date: 2018-06-12